GLABF (Gemina Laboratories) Change In Receivables: $-0.01 Mil (TTM As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gemina Laboratories Change In Receivables?

Gemina Laboratories GLABF -27.59% Change In Receivables is $-0.01 Mil as of Oct. 2025. The stock has 2 warning signs investors should review.

Gemina Laboratories's change in receivables for the quarter that ended in Oct. 2025 was $0.00 Mil. It means Gemina Laboratories's Accounts Receivable stayed the same from Jul. 2025 to Oct. 2025 .

Gemina Laboratories's change in receivables for the fiscal year that ended in Jan. 2025 was $0.00 Mil. It means Gemina Laboratories's Accounts Receivable declined by $0.00 Mil from Jan. 2024 to Jan. 2025 .

Gemina Laboratories's Accounts Receivable for the quarter that ended in Oct. 2025 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Gemina Laboratories's liquidation value for the three months ended in Oct. 2025 was $-4.47 Mil.

Gemina Laboratories  (OTCPK:GLABF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Gemina Laboratories's Days Sales Outstanding for the quarter that ended in Oct. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Gemina Laboratories's accounts receivable are only considered to be worth 75% of book value:

Gemina Laboratories's liquidation value for the quarter that ended in Oct. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=-0.001-4.47+0.75 * 0+0.5 * 0
=-4.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Change In Receivables Related Terms

Gemina Laboratories Change In Receivables Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Change In Receivables Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Change In Receivables
0.00 -0.14 -0.15 0.26 0.00

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.01 -0.00 0.01 0.00

Gemina Laboratories Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Oct. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.01 Mil mean?
Gemina Laboratories (GLABF) has a Change In Receivables of $-0.01 Mil as of Oct. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Gemina Laboratories and its competitors.
Is Gemina Laboratories' Change In Receivables too high?
Gemina Laboratories' current Change In Receivables is $-0.01 Mil.
How does Gemina Laboratories' Change In Receivables compare to VRTX and REGN?
Gemina Laboratories' Change In Receivables of $-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Gemina Laboratories and its competitors. Gemina Laboratories's current Change In Receivables is $-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Change In Receivables of $-0.01 Mil. The current Change In Receivables is $-0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Change In Receivables is $-0.01 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.